Clinical trial · Observational
Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
NCT05816850CI-TRIAL-00099793FIL_FOLL-BIOrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Multicenter, Retrospective, Biological study ancillary to FOLL12 trial to evaluate the role of EZH2 aberrations in patient with FL treated with immunochemotherapy. Moreover, several novel biomarkers of FL will be investigated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EZH2-derived gene expression signature by RNA-Seq | Diagnostic Test | — | UNRESOLVED |
| EZH2 mutations/CNAs by droplet digital PCR (ddPCR) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients enrolled
- description
- Patient affected by advanced Follicular Lymphoma treated with immunochemotherapy in the FIL\_FOLL12 trial
- interventionNames
- Diagnostic Test: EZH2 mutations/CNAs by droplet digital PCR (ddPCR)
- Diagnostic Test: EZH2-derived gene expression signature by RNA-Seq
Primary outcomes (1)
- measure
- Progression free survival
- timeFrame
- From treatment start up to 43 months
- description
- Time between the treatment start and the first documentation of recurrence, progression or death from any cause
Secondary outcomes (2)
- measure
- Response rate
- timeFrame
- From treatment start to 7 months (R-Bendamustine) or from treatment start to 5,6 months (R-CHOP)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient enrolled in the FIL\_FOLL12 trial (documented by the signature of the study informed consent); * Availability of biological samples: bone marrow aspirate, peripheral blood and/or FFPE diagnostic sample (nodal or extranodal); Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.